CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer

Autor: Kathryn AF Pennel, Jean A Quinn, Colin Nixon, Jitwadee Inthagard, Hester C vanWyk, David Chang, Selma Rebus, GPOL Group, Jennifer Hay, Noori N Maka, Campbell SD Roxburgh, Paul G Horgan, Donald C McMillan, James H Park, Antonia K Roseweir, Colin W Steele, Joanne Edwards

Publikováno v: The Journal of Pathology: Clinical Research, Vol 8, Iss 6, Pp 509-520 (2022)

Abstract CXCL8 is an inflammatory chemokine elevated in the colorectal cancer (CRC) tumour microenvironment. CXCR2, the major receptor for CXCL8, is predominantly expressed by neutrophils. In the cancer setting, CXCL8 plays important roles in neutrop

Externí odkaz: https://doaj.org/article/2587601ff4f442529788ab8eca02bcc0

Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.

Autor: Nowak M; Department of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland., Jabbar F; Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK., Rodewald AK; Department of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland., Gneo L; Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK., Tomasevic T; Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK., Harkin A; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Iveson T; University of Southampton, Southampton, UK., Saunders M; The Christie NHS Foundation Trust, Manchester, UK., Kerr R; Department of Oncology, University of Oxford, Oxford, UK., Oein K; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Maka N; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Hay J; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Tomlinson I; Department of Oncology, University of Oxford, Oxford, UK., Sansom O; CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, UK., Kelly C; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Pezzella F; Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Kerr D; Nuffield Department of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK., Easton A; Department of Oncology, University of Oxford, Oxford, UK., Domingo E; Department of Oncology, University of Oxford, Oxford, UK., Koelzer VH; Department of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland; Department of Oncology, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Church DN; Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: dchurch@well.ox.ac.uk.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Sep 17; Vol. 5 (9), pp. 101727.

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Autor: Domingo E; Department of Oncology, University of Oxford, Oxford, United Kingdom.; CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, United Kingdom., Kelly C; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom., Hay J; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Sansom O; CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, United Kingdom., Maka N; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Oien K; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Iveson T; University of Southampton, Southampton, United Kingdom., Saunders M; The Christie NHS Foundation Trust, Manchester, United Kingdom., Kerr R; Department of Oncology, University of Oxford, Oxford, United Kingdom., Tomlinson I; Department of Oncology, University of Oxford, Oxford, United Kingdom., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Harkin A; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom., Nowak M; Department of Pathology and Molecular Pathology, Zurich, Switzerland., Koelzer V; Department of Oncology, University of Oxford, Oxford, United Kingdom.; Department of Pathology and Molecular Pathology, Zurich, Switzerland., Easton A; Department of Oncology, University of Oxford, Oxford, United Kingdom., Boukovinas I; Medical Oncology Unit Department, Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece., Moustou E; Pathology, University Hospital of Heraklion, Crete, Greece., Messaritakis I; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece., Chondrozoumaki M; Laboratory of Tumor Cell Biology, University of Crete - School of Medicine, Heraklion, Greece., Karagianni M; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece., Pagès F; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Université de Paris Cité, Cordeliers Research Center, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Immunomonitoring Platform, Georges Pompidou European Hospital, Paris, France., Arnoux F; VERACYTE, Marseille, France., Lautard C; VERACYTE, Marseille, France., Lovera Y; VERACYTE, Marseille, France., Boquet I; VERACYTE, Marseille, France., Catteau A; VERACYTE, Marseille, France., Galon J; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Université de Paris Cité, Cordeliers Research Center, Paris, France.; VERACYTE, Marseille, France., Souglakos I; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece., Church DN; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 20; Vol. 42 (18), pp. 2207-2218. Date of Electronic Publication: 2024 Mar 14.

JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.

Autor: Pennel KAF; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK. kathryn.pennel@glasgow.ac.uk., Hatthakarnkul P; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Wood CS; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Lian GY; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Al-Badran SSF; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Quinn JA; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Legrini A; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Inthagard J; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Alexander PG; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., van Wyk H; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Kurniawan A; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Hashmi U; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.; University of Glasgow Medical School, Glasgow, G12 8QQ, UK., Gillespie MA; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Mills M; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Ammar A; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Hay J; Glasgow Tissue Research Facility, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK., Andersen D; Bioclavis Ltd, Glasgow, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK., Nixon C; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Rebus S; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Chang DK; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Kelly C; CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, Glasgow, G12 0XH, UK., Harkin A; CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, Glasgow, G12 0XH, UK., Graham J; CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, Glasgow, G12 0XH, UK., Church D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK., Tomlinson I; Edinburgh Cancer Research Centre, IGMM, University of Edinburgh, Crewe Road, Edinburgh, EH4 2XU, UK., Saunders M; The Christie NHS Foundation Trust, Manchester, M20 4BX, UK., Iveson T; Southampton University Hospital NHS Foundation Trust, Southampton, SO16 6YD, UK., Lannagan TRM; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Jackstadt R; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Maka N; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK., Horgan PG; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Roxburgh CSD; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Sansom OJ; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.; CRUK Scotland Institute, Glasgow, G61 1BD, UK., McMillan DC; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK., Steele CW; Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK.; CRUK Scotland Institute, Glasgow, G61 1BD, UK., Jamieson NB; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK., Park JH; Department of Surgery, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK., Roseweir AK; University of Glasgow Medical School, Glasgow, G12 8QQ, UK., Edwards J; School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, G61 1QH, UK.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 01; Vol. 43 (1), pp. 64. Date of Electronic Publication: 2024 Mar 01.

Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.

Autor: Frei AL; Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Life Science Zurich Graduate School, PhD Program in Biomedicine, University of Zurich, Zurich, Switzerland., McGuigan A; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Sinha RR; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Glaire MA; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Jabbar F; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Gneo L; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Tomasevic T; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Harkin A; Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Iveson TJ; Southampton University Hospital NHS Foundation Trust, Southampton, UK., Saunders M; The Christie NHS Foundation Trust, Manchester, UK., Oein K; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Maka N; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Pezella F; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK., Campo L; Department of Oncology, University of Oxford, Oxford, UK., Hay J; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Sansom OJ; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; Cancer Research UK Beatson Institute, Glasgow, UK.; Cancer Research UK Scotland Centre, Edinburgh and Glasgow, UK., Kelly C; Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Tomlinson I; Department of Oncology, University of Oxford, Oxford, UK., Kildal W; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Kerr RS; Department of Oncology, University of Oxford, Oxford, UK., Kerr DJ; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK., Danielsen HE; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway., Domingo E; Department of Oncology, University of Oxford, Oxford, UK.; Cancer Research UK Scotland Centre, Edinburgh and Glasgow, UK., Church DN; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Koelzer VH; Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford, Oxford, UK.

Publikováno v: The journal of pathology. Clinical research [J Pathol Clin Res] 2023 Nov; Vol. 9 (6), pp. 449-463. Date of Electronic Publication: 2023 Sep 11.